Tickets required ($60 when purchased by April 11, 2019). Onsite registration subject to availability.
*Industry technical/scientific staff and representatives are prohibited from registering for Sunrise Workshops
The Mastery program was developed in response to the need to document quality outcomes in patient care, and for individual surgeons to know and be able to report their performance. The goal of this program is to provide the surgeon with the tools to meet this challenge via a voluntary reporting system, open to all surgeons, to report on all breast surgical procedures for both benign and malignant disease.
The Mastery sunrise workshop will highlight the following modules: surgery, percutaneous breast procedures, cancer, risk assessment, and diagnostic imaging. A quick overview of the Quality Payment Program, My Accounts page, and the new patient Survivorship plan will also be included. This is a great introduction workshop but will also be beneficial to current Mastery users.
Navigate the certification process successfully the first time. This workshop will cover the Society's new certification requirements and will provide the view from a reviewer's perspective and the necessary elements to demonstrate your expertise. This session is intended for those pursuing initial certification or recertification. Learn more about the clinical case requirements and gather tips and strategies to ensure success with your initial submission.
In this session we will review the SSO/ASTRO margin guidelines for invasive and noninvasive diseases and apply these guidelines to certain common case scenarios. We will also review the impact of these guidelines on current clinical practice, and discuss clinical scenarios where these guidelines do not apply. Lastly, we will review some of the current technology to assess intraoperative margins and the literature to support these devices.
The optimal timing of post-mastectomy radiation therapy (PMRT) has been a moving target at a time when PMRT use is increasing. This workshop will review the most up-to-date evidence regarding the optimal timing of PMRT in the setting of implant-based and autologous flap breast reconstruction. We will also discuss current data regarding the pros and cons of permanent implant reconstruction in the setting of PMRT.
Neoadjuvant chemotherapy can offer many benefits, including downstaging in the breast and axilla. Selective use of minimally invasive axillary surgery can spare patients significant morbidity. This session will summarize recent trials related to sentinel node surgery after chemotherapy, discuss patient selection, and describe techniques for increasing accuracy of sentinel node biopsy in the setting of neoadjuvant systemic therapy.
This workshop will offer a comprehensive review of technical considerations of nipple-sparing mastectomy including incision placement, flap dissection technique, nipple margin assessment, patient factors, and reconstructive considerations. We will discuss techniques to optimize oncologic and aesthetic outcomes while minimizing complications.
Molecular genomic testing is an important tool in the personalized treatment of breast cancer. Surgeons are in the perfect position to order these tests and should be familiar with them. This workshop will review currently available assays and NCCN/ASCO guidelines regarding multigene assays.
A multidisciplinary approach to the management of locally recurrent breast cancer is essential. The complexities of the management of patients in this setting include discussions regarding the optimal surgical approach (e.g., breast, chest wall, and axillary surgery) and adjuvant treatment considerations (e.g., radiation/re-irradiation therapy and systemic therapy). Treatment has evolved to include the options of repeat breast-conserving surgery, axillary staging, and radiation therapy through partial breast radiation techniques.
Most potential clinical trial patients are seen and managed in the community practice setting. Therefore, breast surgeons who practice in this setting should be equipped to participate and enroll patients in breast cancer trials. This workshop will review best practices for setting up and maintaining a clinical research program in the community practice setting, as well as discuss surgical breast cancer clinical trial opportunities suitable for the community practice setting.
Immunotherapy is a promising treatment approach that has been increasingly integrated into the management of breast cancer patients. This workshop will review the most up-to-date developments in breast cancer immunotherapy, discuss the basics of cancer immunobiology, review commonly used immunotherapy agents, and discuss the potential impact of immunotherapy on surgical therapy.
The national opioid crisis has drawn attention to the need for optimal perioperative pain management. This workshop will discuss best practices for perioperative pain management of breast surgery patients. Additionally, we will review and demonstrate regional blocks that may be used by surgeons to optimize pain control in patients who have undergone lumpectomy, mastectomy, and reconstruction. Lastly, we will review best practices for preventing and reducing perioperative nausea.
Burnout manifests with a wide variety of physical and cognitive symptoms that have profound effects on both the personal and professional lives of affected individuals. About one in three surgical oncologists and general surgeons meet the criteria for burnout. This course will educate breast surgeons about the problem of burnout, signs and symptoms of burnout, and strategies to prevent and manage burnout.
Ablative therapies for the treatment of breast tumors, both benign and malignant, are currently under evaluation in treat and observe clinical trials. While lumpectomy has set a high bar, ablative therapies are approaching that bar and may soon surpass it. Tumor ablation can be accomplished in a single session in the ambulatory or office setting under minimal or no sedation with extremely low morbidity. Cosmesis following tumor ablation is clearly superior when compared to surgery; there is no scar following ablative therapy.